Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.

摘要: Summary Background Aim of this study was to evaluate efficacy, toxicity and tolerability chemotherapy with a combination mitomycin vinorelbine (M/V) in patients advanced non-small cell lung cancer (NSCLC). Methods We enrolled 110 (median age 67 years) locally or metastatic NSCLC, who had no prior progressive disease after at least one regimen. 45 (41%) were ≥70 years old. All received 25mg/m 2 (d1,8) 8mg/m (d1) every 3–4 weeks. Restaging performed by CT-scan two courses M/V according RECIST criteria. Results well tolerated, even poor performance status Median progression free survival 4.4 months. overall 9.0 months 1-year rate 39%. Partial response observed 15% stable 51% patients. Both hematological non-hematological toxicities generally mild. CTC grade 3 included neutropenia 3%, anemia thrombocytopenia 1% suspected pneumonitis 2% Except acute dyspnea 1%, there other 4 treatment associated casualties. There relevant difference outcome between Conclusions seems be well-tolerated effective regimen low NSCLC. It an interesting option for reduced status.